- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01742195
Comparison of Patient Comfort With the Nasal and Oral Insertion of the Endobronchial Ultrasound Bronchoscope
Randomized Study Comparing the Oral and Nasal Routes for Linear Endobronchial Ultrasound
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Linear endobronchial ultrasound (EBUS) now plays a crucial role in the diagnosis, staging, and treatment planning of lung cancer. Most centers perform linear EBUS via the oral route given the larger diameter of the bronchoscope used. However, the feasibility and the diagnostic accuracy of linear EBUS performed through the nose have not been reported. Furthermore, the two routes of insertion have never been compared in terms of patient satisfaction and comfort.
In order to compare the two routes of insertion, consecutive patients referred for a linear endobronchial ultrasound will be recruited. Participants will be randomized to either oral or nasal insertion. All participants will be sedated and will receive local anesthetics in a similar manner. After the procedure, patients will fill a questionnaire regarding their comfort and satisfaction with the procedure.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Institut Universitaire de cardiologie et de pneumologie de Quebec
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- patients older than 18 years of age
- patients referred for a first linear endobronchial ultrasound
Exclusion Criteria:
- Patients who previously underwent an EBUS
- Patients intubated with an endotracheal tube
- Patients under the age of 18
- Patients unable to provide informed consent
- Patients currently taking anticoagulants (therapeutic doses of intravenous or subcutaneous heparin, low-molecular weight heparins, direct thrombin inhibitors or other agents)
- Patients taking anti-platelet therapy other than aspirin (clopidogrel, ticagrelor, prasugrel). A period of 7 days off medication is required before participation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Nasal EBUS insertion
Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
|
|
|
Andet: Oral EBUS insertion
Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient comfort and satisfaction
Tidsramme: Two hours after endobronchial ultrasound
|
Measured by a questionnaire using a 10-point Likert scale for both comfort and satisfaction.
|
Two hours after endobronchial ultrasound
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Physician's assessment of patient comfort
Tidsramme: Immediately after the procedure (within 10 minutes)
|
Measured by a questionnaire using a 10-point Likert scale regarding patient comfort and procedural difficulties.
|
Immediately after the procedure (within 10 minutes)
|
|
Duration of endobronchial ultrasound procedure
Tidsramme: During the procedure
|
Measured in minutes.
|
During the procedure
|
|
Total doses of sedation
Tidsramme: Immediately after the procedure (within 10 minutes)
|
Total doses of each sedative used will be recorded.
|
Immediately after the procedure (within 10 minutes)
|
|
Occurence of pneumothorax, bleeding more than 50ml, oxygen desaturation to less than 90%, epistaxis, cardiac arrhythmia
Tidsramme: During the procedure and up to two hours after
|
During the procedure and up to two hours after
|
|
|
Proportion of adequate cytology specimens in each group
Tidsramme: Days after the procedure (results usually available within 10 days)
|
Days after the procedure (results usually available within 10 days)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Stéphane Beaudoin, MD, Laval University
- Ledende efterforsker: Simon Martel, MD, Laval University
- Ledende efterforsker: Antoine Delage, MD, Laval University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- IUCPQ-20871
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .